Global Assets Advisory’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Global Assets Advisory's CRSP Position: Q3 2026 in Review
Global Assets Advisory sold out of CRISPR Therapeutics (CRSP) in Q3 2026, closing a stake of 4,010 shares — an estimated $222K sold.
Global Assets Advisory first reported a position in CRSP in Q4 2025 and held it in 3 quarters. The position peaked at $228K in Q4 2025. 500 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Global Assets Advisory reported no remaining CRISPR Therapeutics position as of Q3 2026 after selling out during the quarter.
- Global Assets Advisory sold 4,010 CRISPR Therapeutics shares in Q3 2026, an estimated $222K.
- Global Assets Advisory first reported a position in CRISPR Therapeutics in Q4 2025 and held it in 3 quarters.
- Global Assets Advisory's CRISPR Therapeutics position peaked at $228K in Q4 2025.
- 500 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Global Assets Advisory's 13F filing for Q3 2026, filed 28 Oct 2026.